Courtesy of SBHCI. Prognosis of patients with cardiac failure who develop secondary mitral regurgitation due to dilation is uncertain. The COAPT study was carried out in 78 centers across the US and Canada and included patients with moderate to severe mitral regurgitation (3 or 4 crossovers) symptomatic despite optimal medical treatment (OMT). 614 patients were...
TCT 2019 | Mitral Valve-in-Valve: 1-Year Results for Sapien 3 in Mitral Valve Replacement for Degenerated Bioprostheses
Courtesy of SBHCI. The aim of this work was to assess the contemporary outcomes of mitral valve-in-valve using Sapien 3 prostheses, see the differences between trasapical and transseptal access, and establish 1-year mortality predictors. Researchers analyzed retrospectively the data from the Society of Thoracic Surgeons [STS]/American College of Cardiology TVT Registry, which included 1576 patients who had...
ESC 2019 | DAPA-HF: Dapagliflozin Shows Benefit for All Subgroups
Dapagliflozin (a sodium glucose co-transporter 2 [SGLT2] inhibitor), when indicated concomitantly with standard therapy, reduces significantly the risk of worsening heart failure events and cardiovascular events, and improves symptoms in patients with heart failure and reduced ejection fraction according to this new work presented during last Sunday’s scientific sessions at the European Society of Cardiology...
ESC 2019 | PARAGON-HF: Sacubitril/Valsartan Somewhat Disappointing, though a Few Would Benefit.
The combination Sacubitril/valsartan did not reduce the risk of rehospitalization for heart failure or cardiovascular death in patients with cardiac failure symptoms and preserved ejection fraction, according to the new study presented on Sunday at ESC 2019 scientific session in Paris and simultaneously published in NEJM. Despite the negative results, we remain hopeful that this...
All you Need to Know About the SOLACI Sessions 2019
After 12 years, SOLACI returns to Panamá to continue promoting the development of interventional cardiology in Latin America. Do not hesitate to participate in this important event that will undoubtedly be enriching for medical practice and, also, to improve the quality of life of patients in our region. Are you planning on participating in the...
All You Need to Know About Bolivia Sessions 2019
After 2 years, SOLACI returns to Bolivia to continue promoting the development of interventional cardiology in Latin America. Do not hesitate to participate in this important event that will undoubtedly be enriching for medical practice and, also, to improve the quality of life of patients in our region. Are you planning on participating in the...
Dr. Mario Araya Presents the Main Attractions of this Year’s SOLACI Sessions
SOLACI-SBHCI 2019 has come to an end, but SOLACI’s schedule will stay tight until the end of the year. In fact, we are getting closer and closer to Bolivia Sessions 2019 (August 23 – 24 in Cochabamba, Bolivia), Panama Sessions 2019 (September 19 thru 21 in Panama), and Ecuador Sessions 2019 (October 11 – 12 in Manta, Ecuador). That...
SOLACI-SBHCI 2019 | Women in Interventional Cardiology: A Reality Moving Forward in Strides
The presence of women in interventional cardiology is increasing. Year after year, talented female professionals from all over the world join our practices, contributing quality, knowledge, effort, and commitment to the improvement of people’s quality of life. However, this integration progress does include obstacles and problems related to existing gender disparity and inequalities in the...
Supervised Exercise and Revascularization for Intermittent Claudication
The combination of optimal medical treatment plus angioplasty plus supervised exercise seems to be the first line of treatment for patients with intermittent claudication, in terms of maximum walking distance and best quality of life. This combination requires a multidisciplinary team for the best possible results. The aim of this study was to conduct a...
New Promising Alternatives for Mitral Regurgitation
PASCAL transcatheter valve repair system for mitral regurgitation has shown feasibility and safety to treat patients with grade 3+ or 4+, regardless etiology. Regurgitation grade was significantly reduced, and this was accompanied by clinical improvement in functional class, exercise capacity and quality of life. This study soon to be published in J Am Coll Cardiol...